Wilson Lauren E, D'Aloisio Aimee A, Sandler Dale P, Taylor Jack A
Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
Social & Scientific Systems, Inc., Durham, NC, 27703, USA.
Breast Cancer Res. 2016 Jul 5;18(1):61. doi: 10.1186/s13058-016-0720-6.
In a recent case-control study, long-term use of calcium channel blocking drugs was associated with a greater-than-twofold increased breast cancer risk. If prospectively collected data confirm that calcium channel blocker use increases breast cancer risk, this would have major implications for hypertension treatment. The objective of this study was to determine whether women using calcium channel blockers for 10 years or more were at increased risk of developing breast cancer compared with women not using calcium channel blockers.
The Sister Study is a prospective volunteer cohort study of women from the USA and Puerto Rico designed to evaluate environmental and genetic risk factors for breast cancer. Beginning in 2003, women between the ages of 35 and 74 were recruited. They were eligible to participate if they had a sister with breast cancer but had not been diagnosed with breast cancer themselves. In total, 50,884 women enrolled in the cohort between 2003 and 2009; 50,757 women with relevant baseline data and available follow-up data are included in this study. The exposure of interest is current use of calcium channel blocking drugs and the reported duration of use at entry into the cohort. Secondary exposures of interest were the duration and frequency of use for all other subclasses of antihypertensive drugs. Our main outcome is a self-reported diagnosis of breast cancer during the study follow-up period. With patient permission, self-reported diagnoses were confirmed using medical records.
Results showed 15,817 participants were currently using an antihypertensive drug, and 3316 women were currently using a calcium channel blocker at study baseline; 1965 women reported a breast cancer diagnosis during study follow-up. Using Cox proportional hazards modeling, we found no increased risk of breast cancer among women who had been using calcium channel blockers for 10 years or more compared with never users of calcium channel blockers (HR 0.88, 95 % CI 0.58-1.33).
We saw no evidence of increased risk of breast cancer from 10 years or more of current calcium channel blocker use. Our results do not support avoiding calcium channel blocking drugs in order to reduce breast cancer risk.
在最近的一项病例对照研究中，长期使用钙通道阻滞剂与乳腺癌风险增加两倍以上相关。如果前瞻性收集的数据证实使用钙通道阻滞剂会增加乳腺癌风险，这将对高血压治疗产生重大影响。本研究的目的是确定与未使用钙通道阻滞剂的女性相比，使用钙通道阻滞剂10年或更长时间的女性患乳腺癌的风险是否增加。
姐妹研究是一项针对美国和波多黎各女性的前瞻性志愿者队列研究，旨在评估乳腺癌的环境和遗传风险因素。从2003年开始，招募年龄在35岁至74岁之间的女性。如果她们有患乳腺癌的姐妹但自己未被诊断出患有乳腺癌，则有资格参与。2003年至2009年期间，共有50884名女性纳入该队列；本研究纳入了50757名具有相关基线数据和可用随访数据的女性。感兴趣的暴露因素是当前使用钙通道阻滞剂以及进入队列时报告的使用持续时间。感兴趣的次要暴露因素是所有其他抗高血压药物亚类的使用持续时间和频率。我们的主要结局是在研究随访期间自我报告的乳腺癌诊断。经患者许可，使用病历对自我报告的诊断进行了确认。
结果显示，15817名参与者目前正在使用抗高血压药物，3316名女性在研究基线时正在使用钙通道阻滞剂；1965名女性在研究随访期间报告了乳腺癌诊断。使用Cox比例风险模型，我们发现与从未使用过钙通道阻滞剂的女性相比，使用钙通道阻滞剂10年或更长时间的女性患乳腺癌的风险没有增加（风险比0.88，95%置信区间0.58-1.33）。
我们没有发现当前使用钙通道阻滞剂10年或更长时间会增加乳腺癌风险的证据。我们的结果不支持为降低乳腺癌风险而避免使用钙通道阻滞剂。
Zotero 插件